Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2016-10-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of the company's use of idle funds for cash management through entrusted financial products. It details the amounts, counterparties, contract terms, risk control measures, and approvals from the board and shareholders. It does not contain financial statements or detailed financial results but is a regulatory disclosure about financing activities related to cash management. The document length is short (1951 characters) and it is not a report but an announcement of a financial activity. Therefore, it fits best under Capital/Financing Update (CAP).
2016-10-12 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle raised funds. It details the entrusted financial management contracts, approval procedures, risk control measures, and the impact on daily operations. The document is relatively short (1759 characters) and focuses on a specific financing activity related to the use of idle raised funds for guaranteed return financial products. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is an update on financing activities, specifically the use of idle raised funds for cash management and investment in financial products. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-10-12 Chinese
2016年第二次临时股东大会的法律意见书
Regulatory Filings
2016-10-10 Chinese
2016年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2016 second extraordinary general meeting of shareholders of Zhengzhou Antu Bioengineering Co., Ltd. It details the meeting date, attendance, voting results on various proposals, and legal verification of the meeting's validity. There is no financial data or report content, only the voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than a full report or presentation.
2016-10-10 Chinese
2016年第二次临时股东大会会议材料
AGM Information Classification · 100% confidence The document is titled as materials for the 2016 second extraordinary general meeting of shareholders of Autobio Diagnostics Co., Ltd. It contains detailed meeting agenda, procedural documents, and multiple proposals to be voted on by shareholders, including amendments to the company charter and use of idle funds for cash management. The content is typical of meeting materials prepared for a shareholders' meeting, providing information for discussion and voting. It is not a report of financial results, audit, or earnings, nor is it a transcript or announcement of voting results. The document is clearly a set of meeting materials for a shareholders' meeting, which fits the definition of AGM Information (AGM-R). The document length (9067 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement of a meeting or report publication.
2016-09-23 Chinese
关于郑州安图生物工程股份有限公司股票交易异常波动问询函的回复
Regulatory Filings
2016-09-20 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.